Please	type a	plūs si	gn (+)	inside this b		Patent and Trademar	k Of		SB/08A (08-		
Substitute for Form 1449A/PTO  INFORMATION DISCLOSURE STATEMENT BY APPLICANT					Application Number			/522,401	THENT OF COL	HEICE	
					Filing Date			January 19, 2005			
					First Named Inventor			Taishi YOSHIDA			
					Group Art Unit			1646			
	•	•			Examiner Name						
Sheet	Sheet 1 of 3					y Docket Number	04818CIP/HG				
				υ.	S. PATE	ENT DOCUMENTS	1				
Exam. Inits*	Cite No¹	Document Number			Kind Code <sup>2</sup>	Name of Patentee or Applicant		Publication Date MM-DD-YYYY	Relevar Portio		
				FOR	EIGN PA	TENT DOCUMENTS					
Exam Inits	Cite No¹	Offc³	Docum	ment Number	Kind Code⁵	Name of Patentee Applicant	or	Publication Date MM-DD-YYYY	Relevant Portion	T <sup>6</sup>	
/M.F./		WIPO	wo o	01/47935	A2	Metabasis Ther	•	07-05-2001	_		
/M.F./		WIPO WO 99/47549		A1	Ontogen Corp.		09-23-1999				
			i.								

\* EXAMINER: Initial if document considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Date

Considered

06/30/2007

DATE MAILED: May 3, 2005

/Meghan Finn/

Examiner

Signature

<sup>1</sup> Unique citation designation number. <sup>2</sup> See kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>3</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>4</sup> Place a check here if English translation is attached.

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

				r	<del> </del>					
Substitu	te fo	r Form 144	9A/PTO	Application	on Number	10/522,401				
:			•	Filing Da	te	January 19, 2005				
		ISCLOSURE APPLICANT		First Name	ed Inventor	Taishi YOSHIDA				
				Group Art	Unit	1646				
				Examiner	Name					
Sheet	2	of	3	Attorney	Docket Number	04818CIP/HG				
		OTHER	PRIOR ART	- NON-PA	TENT LITERATU	RE DOCUMENTS				
Examiner Initials¹	Cite No.1	Include na page(s)	ame of author , volume-issu	(in CAPITAL e number(s),	LETTERS), title of publisher, city ar	article, title of item, date, ad/or country where published	T²			
/M.F./		WRIGHT, et al., "Anilinoquinazoline Inhibitors of Fructose-1,6-Bisphosphatase Bind at a Novel Allosteric Site: Synthesis, In Vitro Characterization, and X-ray Crystallography", J. Med. Chem., 29 August, 2002 (29.08.02); 45(18): 3865-77								
/M.F./		WRIGHT, et al., "Allosteric inhibition of fructose-1,6-bisphosphatase by anilinoquinazo lines.", <u>Bioorg. Med. Chem.</u> <u>Lett.</u> , 08 January 2001 (08.01.01); 11(1):17-21								
/M.F./		KNOWLER, et al., "Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.", N. Engl. J. Med., 07 February 2002 (07.02.02); 346(6):393-403.								
/M.F./		SARTOR, et al., "Ten-year follow-up of subjects with impaired glucose tolerance: prevention of diabetes by tolbutamide and diet regulation.", <u>Diabetes</u> , 1980 January; 29(1):41-9.								
/M.F./		NOLAN, et al., "Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone.", N. Engl. J. Med., 03 November 1994 (03.11.94); 331(18):1188-93.								
/M.F./		ANTONUCCI, et al., "Impaired glucose tolerance is normalized by treatment with the thiazolidinedione troglitazone.", <u>Diabetes Care</u> , 1997 February; 20(2):188-93.								
Examiner Signatur		/Me	ghan Finn/	Date Considered 06/30/2007						

<sup>\*</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

 $<sup>^{1}</sup>$  Unique citation designation number.  $^{2}$  Place a check here if English translation is attached.

+

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

					<u> </u>		110/500 401			
Substitute for Form 1449A/PTO					Application	on Number	10/522,401			
					Filing Dat	te	January 19, 2005			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT					First Name	ed Inventor	Taishi YOSHIDA			
					Group Art	Unit	1646			
		ř			Examiner 1	Name				
Sheet	3		of	3	Attorney I	Docket Number	04818CIP/HG			
OTHER PRIOR ART - NON-PATENT LITERATURE DOCUMENTS										
Examiner Initials										
/M.F./	•	English translation of International Preliminary Examination Report Form PCT/IPEA/409 in International Application No. PCT/JP2003/009348								
/M:F./		YAMASAKI et al., "Asymptomatic Hyperglycaemia is associated with increased intimal plus medial thickness of the carotid artery", <u>Diabetologia</u> , 1995; 38:585-591								
/M.F./		TOMINAGA et al., "Impaired Glucose Tolerance Is a Risk Factor for Cardiovascular Disease, but Not Impaired Fasting Glucose", Diabetes Care, 1999, 22:920-924								
/M.F./		Journal of Japan Diabetes Society 1999; 42(5):385-404 (English Abstract is attached on pages 402-404)								
/M.F./		"REPORT OF THE EXPERT COMMITTEE ON THE DIAGNOSIS AND CLASSIFICATION OF DIABETES MELLITUS", <u>Diabetes Care</u> , 1997; 20:1183-1197								
/M.F./		ALBERTI, et al., "Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications", <u>Diabetic Medicine</u> , 1998; 15:539-553								
/M.F./		on gl	HOTTA et al., "The inhibitory action of buformin, a biguanide on gluconeogenesis from alanine and its transport system in rat livers", <u>Diabetes Research and Clinical Practice</u> , 1993,19:49-58							
Examiner Signature		/Meghan Finn/ Date Considered 06/30/2007								

<sup>•</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

DATE MAILED: May 3, 2005

 $<sup>^1</sup>$  Unique citation designation number.  $^2$  Place a check here if English translation is attached.

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Application Number OF Rac'd PCT/PTO Substitute for Form 1449A/PTO Herewith Filing Date INFORMATION DISCLOSURE STATEMENT BY APPLICANT First Named Inventor Taishi YOSHIDA Group Art Unit Examiner Name Attorney Docket Number Sheet of 1 04818CIP/HG U.S. PATENT DOCUMENTS Kind Name of Patentee or Publication Relevant Exam. Inite\* Document Number Code<sup>2</sup> Applicant Date MM-DD-YYYY Portion FOREIGN PATENT DOCUMENTS Kind Name of Patentee or Publication Relevant Document Number4 Code<sup>5</sup> Applicant Offc' Inits' Date MM-DD-YYYY Portion /M.F./ WIPO WO 01/47935 **A2** Metabasis Ther. 07-05-2001 /M.F./ 09-23-1999 WIPO WO 99/47549 A1 Ontogen Corp.

EXAMINER: Initial if document considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Date

Considered

06/30/2007

DATE MAILED: January 19, 2005

/Meghan Finn/

Examiner

Signature

¹ Unique citation designation number. ² See kinds of U.S. Patent Documents. ¹ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁴ Place a check here if English translation is attached.

10/522401 DT05 Rec'd PCT/PT0 19 JAN 2005 PTO/SB/08B (08-00)

Please type a plus sign (+) inside this box →

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

					·					
Substitu	te fo	r Form 1449	9A/PTO	Application	cation Number					
<del></del>			· · · · ·	Filing Dat	te	Herewith				
		ISCLOSURE APPLICANT	!	First Name	ed Inventor	Taishi YOSHIDA				
				Group Art	Unit					
				Examiner 1	Name	· · · · · · · · · · · · · · · · · · ·				
Sheet	2	of	2	Attorney 1	Docket Number	04818CIP/HG				
		OTHER	PRIOR ART	- NON-PA	TENT LITERATU	RE DOCUMENTS				
Examiner Initials <sup>1</sup>	Cite No.1					article, title of item, date, d/or country where published	T³			
/M.F./		WRIGHT, et al., "Allosteric inhibition of fructose-1,6-bisphosphatase by anilinoquinazo lines.", <u>J. Med. Chem.</u> , 29 August, 2002 (29.08.02); 45(18): 3865-77								
/M.F./		WRIGHT, et al., "Allosteric inhibition of fructose-1,6-bisphosphatase by anilinoquinazo lines.", <u>Bioorg. Med. Chem.</u> <u>Lett.</u> , 08 January 2001 (08.01.01); 11(1):17-21								
/M.F./		KNOWLER, et al., "Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.", N. Engl. J. Med., 07 February 2002 (07.02.02); 346(6):393-403. (abstract) Medline (PubMed) [online], PMID 11832527								
/M.F./		SARTOR, et al., Ten-year follow-up of subjects with impaired glucose tolerance: prevention of diabetes by tolbutamide and diet regulation.", <u>Diabetes</u> , 1980 January; 29(1):41-9. (abstract) Medline (PubMed) [online], PMID 7380107								
/M.F./		NOLAN, et al., "Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone.", N. Engl. J. Med., 03 November 1994 (03.11.94); 331(18):1188-93. (abstract) Medline (PubMed) [online], PMID 7935656								
/M.F./		ANTONUCCI, et al., "Impaired glucose tolerance is normalized by treatment with the thiazolidinedione troglitazone.", <u>Diabetes Care</u> , 1997 February; 20(2):188-93. (abstract) Medline (PubMed) [online], PMID 9118772								
	-									
Examiner Signature			/Meghan	ı Finn/	Date Considered	06/30/2007				

<sup>\*</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> Place a check here if English translation is attached.